Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 7;13(12):e71655.
doi: 10.1002/ccr3.71655. eCollection 2025 Dec.

Rapid-Onset Drug-Induced Liver Injury Following Amoxicillin-Clavulanate: A Case Report

Shuvam Khadka  1 , Abinash Dev  1 , Pramodman Singh Yadav  2 , Sujan Acharya  1 , Amisha Karki  3 , Leeza Shah  4
Affiliations

Rapid-Onset Drug-Induced Liver Injury Following Amoxicillin-Clavulanate: A Case Report

Shuvam Khadka et al. Clin Case Rep. .

Abstract

Drug-Induced Liver Injury (DILI) is a rare but potentially serious adverse effect of many commonly used medications. DILI is a diagnosis of exclusion and requires a high index of suspicion. Amoxicillin-Clavulanate (A-C) is a widely prescribed antibiotic known to be one of the leading causes of idiosyncratic DILI. Though well documented in Western countries, cases of DILI are less frequently reported in our region. The usual onset of DILI varies from a few days to 8 weeks after initiation of medication. Here, we report a case of an atypically rapid onset of amoxicillin-clavulanate induced liver injury in a 32-year-old female following just two doses.

Keywords: RUCAM; amoxicillin‐clavulanate; case report; drug‐induced liver injury; hepatotoxicity; idiosyncratic reaction.

PubMed Disclaimer

Conflict of interest statement

The patient expressed concern about the severity of her symptoms after taking just two antibiotic doses. She appreciated the explanation provided and has been compliant with follow‐up.The authors declare no conflicts of interest.

References

    1. Sgro C., Clinard F., Ouazir K., et al., “Incidence of Drug‐Induced Hepatic Injuries: A French Population‐Based Study,” Hepatology 36, no. 2 (2002): 451–455. - PubMed
    1. Hosack T., Damry D., and Biswas S., “Drug‐Induced Liver Injury: A Comprehensive Review,” Therapeutic Advances in Gastroenterology 16 (2023): 17562848231163410. - PMC - PubMed
    1. A‐C , LiverTox: Clinical and Research Information on Drug‐Induced Liver Injury [Internet] (National Institute of Diabetes and Digestive and Kidney Diseases, 2012), http://www.ncbi.nlm.nih.gov/books/NBK548517/. - PubMed
    1. Roussel Uclaf Causality Assessment Method (RUCAM) in Drug Induced Liver Injury , LiverTox: Clinical and Research Information on Drug‐Induced Liver Injury [Internet] (National Institute of Diabetes and Digestive and Kidney Diseases, 2012), http://www.ncbi.nlm.nih.gov/books/NBK548272/. - PubMed
    1. DeLemos A. S., Ghabril M., Rockey D. C., et al., “A‐C‐Induced Liver Injury,” Digestive Diseases and Sciences 61, no. 8 (2016): 2406–2416. - PMC - PubMed

LinkOut - more resources